ALK I1171N

CI-VAR-00001963Explore in graph →NP_004295.2:p.Ile1171AsnNM_004304.4:c.3512T>AClinVar 375888 CIViC 588 rs1057519698

Curated evidence

Evidence by cancer (6 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–6 of 6 evidence items across 4 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Anaplastic Large Cell Lymphoma1
NPM1::ALK Fusion AND ALK I1171N	Crizotinib	Predictive	D	Supports Resistance	2	submitted	EID4632 In an in vitro study, cell lines expressing NPM-ALK I1171N, SUPM2CR03 (endogenous expression) and Ba/F3 (overexpression), demonstrated resistance to crizotinib treatment (IC50: 338 nmol/L and IC50: 21… (full text at CIViC) PMID 23239810 · Ceccon et al., 2013 · Open in CIViC	civic
Lung Adenocarcinoma1
v::ALK Fusion AND ALK I1171N	Crizotinib	Predictive	C	Supports Resistance	2	submitted	EID4633 In a stage IV lung adenocarcinoma patient, ALK I1171N was associated with acquired resistance to crizotinib monotherapy. An ALK gene rearrangement had been previously identified and was associated wi… (full text at CIViC)

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Lung Non-Small Cell Carcinoma1
ALK I1171N AND HIP1::ALK Fusion	Alectinib + CrizotinibSequential	Predictive	C	Supports Resistance	2	accepted	EID1483 Case study describes a female (age 58) never-smoker presenting with stage IV NSCLC with an ALK rearrangement (confirmed by fish). Patient was treated with crizotinib (partial response) and alectinib (… (full text at CIViC) PMID 25393796 · Ou et al., 2014 · Open in CIViC	civic

Pleural Malignant Mesothelioma3
EML4::ALK Fusion AND ALK G1202R AND ALK I1171N AND ALK L1196M	Lorlatinib	Predictive	C	Supports Resistance	3	accepted	EID11114 This case report describes a 33 year-old non-smoker with no known exposure to asbestos who was diagnosed with stage IIIB malignant pleural mesothelioma. Panel next generation sequencing (NGS) of 520 g… (full text at CIViC) PMID 32600123 · Hu et al., 2020 · Open in CIViC	civic
EML4::ALK Fusion AND ALK I1171N AND ALK L1196M	Alectinib	Predictive	C	Supports Resistance	4	accepted	EID11115 A 33 year old male with no smoking history or known exposure to asbestos was diagnosed with malignant pleural mesothelioma (MPM). EML4::ALK was found using a panel of 520 genes in NGS, and the patient… (full text at CIViC) PMID 32600123 · Hu et al., 2020 · Open in CIViC	civic
EML4::ALK Fusion AND ALK I1171N AND ALK L1196M	Lorlatinib	Predictive	C	Supports Sensitivity Response	3	accepted	EID11113 This case report describes a 33 year-old non-smoker with no known exposure to asbestos who was diagnosed with stage IIIB malignant pleural mesothelioma. Panel next generation sequencing (NGS) of 520 g… (full text at CIViC) PMID 32600123 · Hu et al., 2020 · Open in CIViC	civic